ArticleDiabetologia1996
Interleukin-12 gene expression is associated with rapid development of diabetes mellitus in non-obese diabetic mice.
Article in Diabetologia, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Assessing the association of rs7574865 STAT4 gene variant and type 1 diabetes mellitus among Egyptian patients.Journal, genetic engineering & biotechnology · 2021Article
- Article
- High Interleukin-12 Levels May Prevent an Increase in the Amount of Fungi in the Gastrointestinal Tract during the First Years of Diabetes Mellitus Type 1.Disease markers · 2016Article
- Vasoregression: A Shared Vascular Pathology Underlying Macrovascular And Microvascular Pathologies?Omics : a journal of integrative biology · 2015Review
- Biomarkers in diabetic retinopathy and the therapeutic implications.Mediators of inflammation · 2013Review
- Cannabidiol arrests onset of autoimmune diabetes in NOD mice.Neuropharmacology · 2008Article
- Serum TNF-alpha level predicts nonproliferative diabetic retinopathy in children.Mediators of inflammation · 2007Article
- Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil.Clinical and experimental immunology · 2002Article
- Polymorphisms in the Il12b gene affect structure and expression of IL-12 in NOD and other autoimmune-prone mouse strains.Genes and immunity · 2002Article
- Review
- Endogenous interleukin-12 only plays a key pathogenetic role in non-obese diabetic mouse diabetes during the very early stages of the disease.Immunology · 1999Article
- Regulation of inducible nitric oxide synthase expression in beta cells by environmental factors: heavy metals.The Biochemical journal · 1999Article
- Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice.The Journal of clinical investigation · 1998Article
- 1,25-Dihydroxyvitamin D3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes.Clinical and experimental immunology · 1998Article
- alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10.The Journal of experimental medicine · 1998Article
- Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2.The Journal of clinical investigation · 1997Article
- The role of interleukin-1 in the pathogenesis of IDDM.Diabetologia · 1996Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A single dose of cyclophosphamide (250 mg/kg) is known to synchronize and accelerate development of diabetes in non-obese diabetic mice. We have reported previously that cyclophosphamide treatment of 10-week-old female non-obese diabetic mice induces a shift from T-helper type 2 to T-helper type 1 activity in islet lesions. We now show that this shift in regulatory T-cell function is preceded by the expression of interleukin-12 in the islets as well as in the spleen. In the spleen macrophages were identified as the interleukin-12 expressing cell type. At the same time there was little induction of tumour necrosis factor alpha gene expression by macrophages. Since interleukin-12 is well known to drive T-helper cell type 1 responses we assume that interleukin-12 released by macrophages mediates the accelerating effect of cyclophosphamide on islet inflammation in non-obese diabetic mice. mRNA expression of the p40 chain of interleukin-12 in response to cyclophosphamide was not seen in macrophages of Balb/c mice and thus represents an immune abnormality of non-obese diabetic mice favouring T-helper type 1 reactions.
Indexed as
Identifiers
8720612What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.